Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

15-Year watch begins for CAR T-Cell therapy recipients

NCT ID NCT06652633

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 28 times

Summary

This study follows about 546 people who have already received a Galapagos CAR T-cell therapy for blood cancers. Researchers will track them for 15 years to check for long-term side effects, how long the treatment lasts in the body, and overall survival. No new treatment is given—this is just monitoring to meet safety guidelines.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Academisch Medisch Centrum

    RECRUITING

    Amsterdam, 1105 AZ, Netherlands

  • Amsterdam UMC

    RECRUITING

    Amsterdam, 1081 HV, Netherlands

  • Antwerp University Hospital

    RECRUITING

    Edegem, 2650, Belgium

  • Centre Hospitalier Universitaire (CHU) De Liège

    RECRUITING

    Liège, 4032, Belgium

  • Hospital Clinic De Barcelona

    RECRUITING

    Barcelona, 08036, Spain

  • Leids University Medical Center (LUMC)

    RECRUITING

    Leiden, 2333 ZA, Netherlands

Conditions

Explore the condition pages connected to this study.